New England Journal of Medicine publishes outcomes from practice-changing E1910 trial for patients with BCR::ABL1-negative B-cell precursor acute lymphoblastic leukemia
A significant survival improvement for adults with newly diagnosed BCR::ABL1-negative B-cell precursor acute lymphoblastic leukemia is published today by the New England Journal of Medicine. The practice-changing finding is from the randomized phase 3 study E1910 (NCT02003222), which evaluated blinatumomab immunotherapy in patients who were